Linagliptin Film-Coated Tablet Granulation Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of linagliptin or its pharmaceutically acceptable salt face challenges with stability, content uniformity, flowability, and compressibility, particularly in solid dosage forms where amine group-containing DPP-4 inhibitors like linagliptin tend to react with excipients, leading to undesirable properties.
Innovation Solution
A film coated tablet preparation process using fluid-bed spray granulation, involving mixing linagliptin with a disintegrant and filler, dissolving a binder in a solvent to create a granulation solution, and then spray granulating the mixture, which enhances stability, uniformity, and compressibility, and includes specific proportions and types of excipients like microcrystalline cellulose and polyvinylpyrrolidone to improve dissolution and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If linagliptin is used in small proportion in solid dosage forms, then the dosage requirement is met, but content uniformity deteriorates due to poor distribution of active ingredient
Solution Approach 1:
The patent combines linagliptin with excipients in a wet granulation process to form uniform granules. The active ingredient is mixed with binders, fillers, and disintegrants to create a homogeneous mixture that ensures uniform distribution of the low-dose linagliptin throughout the tablet batch, resolving the content uniformity issue.
Solution Approach 2:
The patent changes the physical state and size parameters by converting fine powders into granules with specific size ranges (0.5-2.5mm). This granulation process transforms the physical form of the mixture, improving flow properties and ensuring uniform distribution of the active ingredient during compression.
2Reliability
If linagliptin is used in solid dosage forms, then the therapeutic effect is achieved, but stability deteriorates due to reaction between amine group and excipients
Solution Approach 1:
The patent uses specific excipients as intermediaries between linagliptin and the tablet matrix. Binders like hydroxypropyl methylcellulose and disintegrants like croscarmellose sodium are selected to be chemically compatible with the amine group of linagliptin, preventing unwanted reactions while maintaining tablet integrity and therapeutic efficacy.
Solution Approach 2:
The patent creates a chemically inert environment by selecting excipients that do not react with the amine group of linagliptin. The formulation uses inert binders, fillers, and coating materials that protect the active ingredient from degradation reactions, ensuring long-term chemical stability.
3Reliability
If linagliptin is used in solid dosage forms, then the treatment is effective, but flowability deteriorates due to poor flow properties of active ingredient
Solution Approach 1:
The patent changes the size and shape parameters of the powder mixture by converting fine powders into granules with optimized size distribution (0.5-2.5mm). This granulation process improves interparticle friction and flow characteristics, enabling the low-dose linagliptin formulation to flow smoothly during tablet compression.
4Reliability
If linagliptin is used in solid dosage forms, then the therapeutic benefit is achieved, but compressibility deteriorates due to poor compressibility of active ingredient
Solution Approach 1:
The patent combines linagliptin with compressible excipients such as microcrystalline cellulose and mannitol in the granulation process. These excipients provide compressibility and binding properties that compensate for the poor compressibility of linagliptin, enabling formation of robust tablets with adequate hardness and strength.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves excellent content uniformity, improved flowability, and enhanced compressibility, ensuring long-term stability and bioavailability of linagliptin, while preventing segregation and reactivity issues, thus overcoming the limitations of prior art.
Implementation Method 1
Dissolving at least binder in a solvent and obtained a granulation solution, Granulating the granulation solution with the mixture using spray granulation
Implementation Method 2
Granulating the granulation solution with the mixture at step (a) using spray granulation
Data Source
AI summary
The present invention relates to a process for the preparation of a film coated tablet formulation comprising linagliptin or a pharmaceutically acceptable salt thereof. The process is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the disadvantages of active ingredient.